| Primary | Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12 | | FAS included all participants who were randomized. Here, "number of participants analyzed" signifies those participants who were evaluable for this outcome measure. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG0001.0± 20.89
- OG001-55.6± 29.17
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| LS-mean difference, associated 95% confidence intervals and p values from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographical region, triglyceride subgroup. | Mixed Model Repeated Measures (MMRM) | | <0.001 | | Least Square (LS) Mean Difference | -57.0 | Standard Error of the Mean | 2.00 | 2-Sided | 95 | -61.0 | -53.1 | | | | | Superiority or Other | | |
|
| Secondary | Percent Change From Baseline in Total Cholesterol (TC) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Non- High Density Lipoprotein-Cholesterol (Non HDL-C) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Lipoprotein(a) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) at Week 12 in Participants With Primary Hyperlipidemia | Participants with primary hyperlipidemia are defined as participants with triglycerides (TG) level less than (<) 200 milligram per decilitre (mg/dL) (2.26 millimoles per litre [mmol/L]) at pre-randomization. | FAS included all participants who were randomized. Here, "number of participants analyzed" signifies those participants who were evaluable for this outcome measure. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) at Week 12 in Participants With Mixed Dyslipidemia | Participants with mixed dyslipidemia are defined as TG level greater than or equal to (>=) 200 mg/dL (2.26 mmol/L) at pre-randomization. | FAS included all participants who were randomized. Here, "number of participants analyzed" signifies those participants who were evaluable for this outcome measure. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Week 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52 by Triglyceride Cut-off | Percent change from baseline in fasting LDL-C among participants with TG cut-off of <200 mg/dL and >=200 mg/dL (2.26 mmol/L) were reported in this outcome measure. | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Fasting Triglyceride (TG) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in ApolipoproteinA-I (ApoA-I) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in ApolipoproteinA-II (ApoA-II) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | percent change | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Fasting Low Density Lipoprotein-C (LDL-C) at Week 12 by Trigylceride Cut-Off | Absolute change from baseline among participants with TG cut-off of <200 mg/dL and >=200 mg/dL (2.26 mmol/L) were reported in this outcome measure. | FAS included all participants who were randomized.'Number of participants analyzed' signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Total Cholesterol (TC) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Lipoprotein(a) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Ratio of Fasting Total Cholesterol to High Density Lipoprotein-Cholesterol (TC/HDL-C Ratio) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | ratio | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Absolute Change From Baseline in Ratio of Apolipoprotein B to ApolipoproteinA-I (ApoB/ApoA-I Ratio) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | ratio | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percentage of Participants Achieving Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (2.59 Millimoles Per Litre) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Number | | percentage of participants | | Week 12, 24 and 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Percentage of Participants Achieving Fasting Low Density Lipoprotein-Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (1.81 Millimoles Per Litre) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Number | | percentage of participants | | Week 12, 24 and 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Secondary | Plasma PF-04950615 Concentrations at Week 12, 24 and 52 | | Analysis set included participants who received at least 1 dose of PF-04950615. Here, 'n' signifies those participants who were evaluable at specified time points. | Posted | | Mean | Standard Deviation | microgram per milliliter | | Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| | |
| Secondary | Number of Participants With Adverse Events (AEs) Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions | Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthritis, myalgia's, polysynovitis, fever and if severe then included glomerulonephritis as well. Injection site reactions included injection site bruising, discolouration, erythema, haematoma, haemorrhage, nodule, induration, pain, pruritus and rash. Participants with type 1 or type 3 hypersensitivity reactions and participants with injection site reactions were reported in this outcome measure. | Safety analysis set included all participants who received at least 1 dose of study treatment. | Posted | | Number | | participants | | Baseline up to the end of study (up to 58 weeks) | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
|
| Secondary | Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) | Percentage of participants with at least 1 positive ADA titer or 1 positive nAb titer were reported. Participants with their ADA titer >=6.23 were considered to be ADA positive and participants with their nAb titer >=1.58 were considered to be nAb positive. | Safety analysis set included all participants who received at least 1 dose of study treatment. Participants who received at least 1 dose of PF-04950615 were evaluable for this outcome measure. Here, "number of participants analyzed" signifies those participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | Baseline up to the end of study (up to 58 weeks) | | | | ID | Title | Description |
|---|
| OG000 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Other Pre-specified | Absolute Change From Baseline in Triglyceride (TG) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Other Pre-specified | Absolute Change From Baseline in ApolipoproteinA-I (ApoA-I) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |
| Other Pre-specified | Absolute Change From Baseline in ApolipoproteinA-II (ApoA-II) at Week 12, 24 and 52 | | FAS included all participants who were randomized. Here, 'n' signifies those participants who were evaluable at specified time points for each arm. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, Week 12, 24, 52 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. | | OG001 | PF-04950615 150 mg | Participants received single dose of PF-04950615 150 mg subcutaneous injection once in every 2 weeks over a period of 52 weeks. Participants were followed up to 58 weeks. |
| |